Our in‐depth understanding of the pVHL‐HIF1/2α axis in ccRCC has contributed significantly to the development of molecular‐based therapeutic strategies for advanced ccRCC cases (Choueiri and Kaelin Jr. 2020). The gene discussed is HIF1A; the disease is nonpapillary renal cell carcinoma.